Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein–Barr virus‐associated T‐cell lymphoma: Nuclear factor‐κB pathway as a potential therapeutic target
Authors:
- 11 July 2007
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 98 (9) , 1281-1287
Abstract
Epstein–Barr virus (EBV) can infect T lymphocytes and manifests as hemophagocytic lymphohistiocytosis (HLH), a distinct entity of hemophagocytic syndrome (HPS) characterized by fever, hepatosplenomegaly, cytopenia, hypercytokinemia, and systemic macrophage activation with hemophagocytosis. In a substantial percentage of HLH patients, the disease may relapse or progress to T‐cell lymphoma in months to years. In the present review, the authors summarize the previous studies on the pathogenesis of HLH and the potential mechanism for the progression of disease from HLH to T‐cell lymphoma. The infection of T cells by EBV could activate T cells to secrete proinflammatory cytokines, particularly tumor necrosis factor‐α (TNF‐α), which subsequently activate macrophages. EBV latent membrane protein‐1 (LMP‐1) is the viral product responsible for the activation of the TNF receptor (TNFR) associated factors/nuclear factor‐κB (NF‐κB)/ERK pathway to enhance cytokine secretion mediated through the suppression of the SAP/SH2D1A gene. The activation of NF‐κB will confer resistance to TNF‐α‐induced apoptosis on EBV‐infected T cells through the down‐regulation of TNFR‐1. Consistent with in vitro observations, EBV‐associated T or natural killer/T‐cell lymphoma showed constitutive activation of NF‐κB, explaining its drug resistance, hypercytokinemia, and poor prognosis. Therefore, similar to other inflammation‐associated cancers, HLH provides a unique model to study the mechanism of disease progression from a benign virus‐infected disorder (HLH) to T‐cell lymphoma. Inhibition of the NF‐κB signal pathway should provide a potential target for the treatment of HLH and EBV‐associated T‐cell lymphoma. (Cancer Sci 2007; 98: 1281–1287)Keywords
This publication has 69 references indexed in Scilit:
- Epstein-Barr Virus (EBV) Latent Membrane Protein-1 Down-Regulates Tumor Necrosis Factor-α (TNF-α) Receptor-1 and Confers Resistance to TNF-α-Induced Apoptosis in T CellsThe American Journal of Pathology, 2007
- Emergence of Anti-Red Blood Cell Antibodies Triggers Red Cell Phagocytosis by Activated Macrophages in a Rabbit Model of Epstein-Barr Virus-Associated Hemophagocytic SyndromeThe American Journal of Pathology, 2007
- NF-κB functions as a tumour promoter in inflammation-associated cancerNature, 2004
- Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonistsThe Lancet Oncology, 2004
- Epstein-Barr Virus Immediate-Early Protein BZLF1 Inhibits Tumor Necrosis Factor Alpha-Induced Signaling and Apoptosis by Downregulating Tumor Necrosis Factor Receptor 1Journal of Virology, 2004
- Munc13-4 Is Essential for Cytolytic Granules Fusion and Is Mutated in a Form of Familial Hemophagocytic Lymphohistiocytosis (FHL3)Cell, 2003
- Epstein-Barr virus: exploiting the immune systemNature Reviews Immunology, 2001
- Perforin Gene Defects in Familial Hemophagocytic LymphohistiocytosisScience, 1999
- Nasal Lymphomas in Japan: A High Prevalence of Epstein-Barr VirusTypeA and Deletion Within the Latent Membrane Protein GeneLeukemia & Lymphoma, 1999
- T-Cell Lymphomas Containing Epstein–Barr Viral DNA in Patients with Chronic Epstein–Barr Virus InfectionsNew England Journal of Medicine, 1988